Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention - Wikidata - thesis-toulmin - TriplyDB

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

http://www.wikidata.org/entity/Q28067145

about

Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer.The dawn of vaccines for cancer prevention.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.as a Vector for Cancer Immunotherapy: Current Understanding and Progress

P2860

Q38648122-6F54BFBA-5F47-43E9-8599-18062D9629F8 Q43760187-FFF9EC81-E6C2-4632-B7DA-5307A7A079B3 Q49566629-ACDBD5BC-21F7-46D4-8DBA-F7BF3FF96ED6 Q55240690-AA463204-5FBC-4792-BE62-1432DC50523F Q55466488-4DB106AA-E86A-4C7C-AF0D-1734C1E26867 Q58924835-57D91848-92CE-4ACF-AC73-BED58EDBF782

P2860

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

http://www.wikidata.org/entity/Q28067145

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@ast

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@en

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@nl

type

label

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@ast

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@en

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@nl

prefLabel

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@ast

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@en

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@nl

P1433

Q28067145-C14A6B27-40AD-4A38-B43E-52019CBB5511

P1476

Q28067145-EABC39E6-1813-4EA7-BC6C-83A0817E2599

P2093

Q28067145-32517B86-F9AC-4A1A-86A8-E23F02CA4DF0

Q28067145-50E5ED75-0BEC-4EDF-B506-8C7876765515

Q28067145-8DF7EA6A-A927-4D2F-9325-FED891FCF735

Q28067145-DBA339B5-78B4-47A3-8AA4-A0C1E7A8C673

Q28067145-EA1C30FF-7152-4692-B51A-6C6C6F170549

P2860

Q28067145-05191260-D0FB-4C9C-9BF8-7CBB4B7DFEED

Q28067145-073A356E-A0DA-46A7-AD24-322AF8E4CF3A

Q28067145-0DBCC433-78D5-4D75-9402-93AA5E20F668

Q28067145-11C9587A-91A0-4AA7-9673-3BF3B8C84DF0

Q28067145-174D90CE-0675-43BC-B509-076669E8341C

Q28067145-1907FDEE-F5FB-4B90-B786-D34AA5E603CE

Q28067145-1A96EDA0-9FAF-4831-9A0D-DDE05FD8A0FA

Q28067145-22C17BE4-8E25-47E8-B9BF-92B4DB0BBC96

Q28067145-234789A5-FCE0-4506-8E70-8426B9C9B000

Q28067145-23545155-F821-4225-BC69-DAB550C2515D

P304

Q28067145-0149C660-4AAF-4473-8532-2C5EC4D8A330

P31

Q28067145-1A247565-9871-4752-BF20-A81F7073CE97

P3181

Q28067145-D477DD9D-89D7-4F1F-9DBD-E271B2D7ECA5

P356

Q28067145-49560F54-757B-44D3-AFE7-7ABB14E56CE9

P407

Q28067145-5C8E24AC-F09B-4B87-BE84-C2BD26D702EE

P478

Q28067145-715BBA38-BCD4-424F-A9F7-F5F88BE8DAE4

P577

Q28067145-886B3484-2324-4EF7-895F-CE0F606C7963

P698

Q28067145-500789EE-6457-4FC1-9E22-8A888325EA58

P932

Q28067145-EE762616-732E-4A20-BF7D-0A0D9BD42FAB

P3181

P356

FPHAR.2016.00356

P1433

Frontiers in Pharmacology

P1476

Restoring Lost Anti-HER-2 Th1 ...... ines in Therapy and Prevention

@en

P2093

Brian J. Czerniecki

http://www.w3.org/2001/XMLSchema#string

Cinthia Rosemblit

http://www.w3.org/2001/XMLSchema#string

Lucy M. De La Cruz

http://www.w3.org/2001/XMLSchema#string

M. Catherine Lee

http://www.w3.org/2001/XMLSchema#string

Nadia F. Nocera

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

The blockade of immune checkpoints in cancer immunotherapy

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

The role of regulatory T cells in cancer.

P304

356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3103954

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FPHAR.2016.00356

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27766079

http://www.w3.org/2001/XMLSchema#string

P932

5052279

http://www.w3.org/2001/XMLSchema#string